NCT07699991 A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors
| NCT ID | NCT07699991 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Anatomic Stage 0 Breast Cancer AJCC v8 |
| Study Type | INTERVENTIONAL |
| Enrollment | 330 participants |
| Start Date | 2026-12-09 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 330 participants in total. It began in 2026-12-09 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies whether a navigation program improves survivorship support service participation among survivors of breast cancer that has not spread from where it first started (primary site) to other places in the body (non-metastatic). Advances in treatment have caused the number of breast cancer survivors to grow. As this number increases, there are reported unmet supportive care needs in this population, including psychological distress and limitations in physical functioning. To address these needs, many cancer centers offer programming on a variety of topics including psychological services, exercise counseling, and nutrition counseling. Research has shown that while interest in these survivorship programs is high, participation remains low, especially among minority women. Navigation is a healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care. The navigation program in this trial is specifically focused on helping breast cancer survivors schedule and attend survivorship consultation appointments as well as providing additional support to underserved/vulnerable patients. A navigation program may be effective in improving survivorship support service participation among non-metastatic breast cancer survivors.
Eligibility Criteria
Inclusion Criteria: * GENERAL INCLUSION (PRIMARY OBJECTIVE): Ages 18+ * GENERAL INCLUSION (PRIMARY OBJECTIVE): Diagnosed with non-metastatic breast cancer * GENERAL INCLUSION (PRIMARY OBJECTIVE): Received care at Stefanie Spielman Breast Center * COACHING INCLUSION (SECONDARY OBJECTIVE): Referred patients who fall under any of the following: * Black and/or Hispanic * Ages ≥ 70 * Reside in a ZIP code classified as rural by United States Department of Agriculture (USDA) Rural-Urban Commuting Area (RUCA) codes Exclusion Criteria: * Metastatic breast cancer at time of referral * Prisoners or individuals unable to consent * Non-English and non-Spanish speakers
Contact & Investigator
The Ohio State University Comprehensive Cancer Center
✉ OSUCCCClinicaltrials@osumc.edu📞 1-800-293-5066
Bridget A Oppong, MD, MPH
PRINCIPAL INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT07699991 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Anatomic Stage 0 Breast Cancer AJCC v8. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07699991 currently recruiting?
Yes, NCT07699991 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.
Where is the NCT07699991 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT07699991 clinical trial?
NCT07699991 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Bridget A Oppong, MD, MPH at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 330 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.